Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziconotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 1.00 |
| ▸ | ELANE | P08246 | 4/20 | 0.54 |
| ▸ | CTSG | P08311 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | NPR1 | P16066 | 1/20 | 0.50 |
| ▸ | NPR3 | P17342 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | MC3R | P41968 | 1/20 | 0.47 |
| ▸ | MC1R | Q01726 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziconotide SCHEMBL29369952 | 1.00 | CACNA1B (1.00) | CACNA1BELANECTSGITGB3ITGB1 | |
| Ziconotide SCHEMBL28142155 | 0.94 | CACNA1B (0.89) | CACNA1BELANECTSGITGB3ITGB1 | |
| Ziconotide SCHEMBL29360120 | 0.92 | CACNA1B (0.85) | CACNA1BELANEITGB3PLAUSLC6A3 | |
| SCHEMBL29432871 | 0.90 | CACNA1B (0.82) | CACNA1BELANECTSGITGB3ITGB1 | |
| SCHEMBL29405845 | 0.90 | CACNA1B (0.82) | CACNA1BELANECTSGITGB3ITGB1 | |
| Kalata B8 SCHEMBL30173419 | 0.82 | CACNA1B (0.70) | CACNA1BELANECTSGITGB3ITGB1 | |
| SCHEMBL20910081 | 0.82 | CACNA1B (0.69) | CACNA1BELANECTSGPLAUKDM4A | |
| SCHEMBL19232225 | 0.81 | CACNA1B (0.68) | CACNA1BELANECTSGPLAUKDM4A | |
| SCHEMBL16976079 | 0.79 | CACNA1B (0.64) | CACNA1BELANECTSGITGB3ITGB1 | |
| SCHEMBL19232199 | 0.79 | CACNA1B (0.65) | CACNA1BELANECTSGITGB3ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| US-12466851-B2 | Manufacture of disulfide bonded peptides | BACHEM HOLDING AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| CN-114787356-B | Antisense oligonucleotides and their use in the treatment of pain | INSERM(法国国家健康医学研究院) | 2025-06-13 | — | — | CN | disclosed |
| US-12257352-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-25 | — | — | US | disclosed |
| CN-112672763-B | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2025-03-25 | — | — | CN | disclosed |
| US-12186432-B2 | Preparation method of sustained-release microparticles | AC PHARMACEUTICALS CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| CN-1205185-C | Nitrogen-containing cyclic compound and pharmaceutical composition containing the same | EISAI CO LTD (JP) | 2005-06-08 | — | — | CN | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| CN-1395562-A | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2003-02-05 | — | — | CN | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| CN-1310709-A | N, N-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2001-08-29 | — | — | CN | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | CACNA1B 4185/4885ELANE 69/4885CTSG 425/4885 |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | CACNA1B 2/4885ELANE 4242/4885CTSG 4137/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | CACNA1B 1864/4885ELANE 1785/4885CTSG 854/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | CACNA1B 3394/4885ELANE 2624/4885CTSG 1777/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | CACNA1B 1/4885ELANE 4141/4885CTSG 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.